-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Relay Therapeutics, Raises Price Target to $18

Benzinga·04/28/2026 12:45:30
Listen to the news
Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform and raises the price target from $14 to $18.